209 related articles for article (PubMed ID: 29977164)
1. Pharmacological properties of betrixaban.
Huisman MV; Klok FA
Eur Heart J Suppl; 2018 May; 20(Suppl E):E12-E15. PubMed ID: 29977164
[TBL] [Abstract][Full Text] [Related]
2. Betrixaban for prevention of venous thromboembolism in acute medically ill patients.
Beyer-Westendorf J; Verhamme P; Bauersachs R
Eur Heart J Suppl; 2018 May; 20(Suppl E):E16-E22. PubMed ID: 29977165
[TBL] [Abstract][Full Text] [Related]
3. Direct oral anticoagulants for extended thromboprophylaxis in medically ill patients: meta-analysis and risk/benefit assessment.
Al Yami MS; Kurdi S; Abraham I
J Blood Med; 2018; 9():25-34. PubMed ID: 29503590
[TBL] [Abstract][Full Text] [Related]
4. Extended thromboprophylaxis in the acutely ill medical patient after hospitalization - a paradigm shift in post-discharge thromboprophylaxis.
Mahan CE; Burnett AE; Fletcher ML; Spyropoulos AC
Hosp Pract (1995); 2018 Feb; 46(1):5-15. PubMed ID: 29171776
[TBL] [Abstract][Full Text] [Related]
5. Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolism.
Nafee T; Gibson CM; Yee MK; Alkhalfan F; Chi G; Travis R; Mir M; Kalayci A; Jafarizade M; Ganti A; Kazmi SH; Ghaffarpasand E; Pitliya A; Datta S; Sharfaei S; Alihashemi M; Elsaiey A; Qamar I; Jahansouz M; Talib U; Kahe F; Habibi S; Abdelwahed M; Tariq F; Kaur M; Younes A; Walia SS; Singh A; Dildar SM; Afzal MK; Kerneis M
Expert Rev Cardiovasc Ther; 2018 Nov; 16(11):845-855. PubMed ID: 30296387
[TBL] [Abstract][Full Text] [Related]
6. Betrixaban: A New Oral Factor Xa Inhibitor for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients.
Garland SG; DeRemer CE; Smith SM; Gums JG
Ann Pharmacother; 2018 Jun; 52(6):554-561. PubMed ID: 29338293
[TBL] [Abstract][Full Text] [Related]
7. Direct oral anticoagulants for extended-duration thromboprophylaxis in hospitalized medically ill patients: are we there yet?
Al Yami MS; Alfayez OM; Kurdi SM; Alsheikh R
J Thromb Thrombolysis; 2017 Jul; 44(1):1-8. PubMed ID: 28197755
[TBL] [Abstract][Full Text] [Related]
8. Betrixaban for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients: Putting the APEX Results into Practice.
Miller KM; Brenner MJ
Drugs; 2019 Feb; 79(3):291-302. PubMed ID: 30719631
[TBL] [Abstract][Full Text] [Related]
9. Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Chi G; Goldhaber SZ; Kittelson JM; Turpie AGG; Hernandez AF; Hull RD; Gold A; Curnutte JT; Cohen AT; Harrington RA; Gibson CM
J Thromb Haemost; 2017 Oct; 15(10):1913-1922. PubMed ID: 28762617
[TBL] [Abstract][Full Text] [Related]
10. Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy.
Chi G; Gibson CM; Kalayci A; Cohen AT; Hernandez AF; Hull RD; Kahe F; Jafarizade M; Sharfaei S; Liu Y; Harrington RA; Goldhaber SZ
Intensive Care Med; 2019 Apr; 45(4):477-487. PubMed ID: 30778649
[TBL] [Abstract][Full Text] [Related]
11. Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative.
Barkoudah E; Piazza G; Hecht TEH; Grant P; Deitelzweig S; Fang MC; Fanikos J; Kao CK; Barnes GD; Chen T; Ramishvili T; Schnipper JL; Goldstein JN; Ruff CT; Kaatz S; Schwartz A; Connors JM; Goldhaber SZ
Am J Med; 2020 May; 133 Suppl 1():1-27. PubMed ID: 32362349
[TBL] [Abstract][Full Text] [Related]
12. Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban).
Gibson CM; Chi G; Halaby R; Korjian S; Daaboul Y; Jain P; Arbetter D; Goldhaber SZ; Hull R; Hernandez AF; Gold A; Bandman O; Harrington RA; Cohen AT;
Circulation; 2017 Feb; 135(7):648-655. PubMed ID: 27881569
[TBL] [Abstract][Full Text] [Related]
13. Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more.
Ageno W; Lopes RD; Yee MK; Hernandez A; Hull RD; Goldhaber SZ; Gibson CM; Cohen AT
J Thromb Haemost; 2019 Dec; 17(12):2089-2098. PubMed ID: 31392827
[TBL] [Abstract][Full Text] [Related]
14. Betrixaban: A Novel Factor Xa Inhibitor for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients.
Lee K; Cham S; Lam S
Cardiol Rev; 2018; 26(6):331-338. PubMed ID: 30067518
[TBL] [Abstract][Full Text] [Related]
15. The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study.
Cohen AT; Harrington R; Goldhaber SZ; Hull R; Gibson CM; Hernandez AF; Kitt MM; Lorenz TJ
Am Heart J; 2014 Mar; 167(3):335-41. PubMed ID: 24576517
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of betrixaban extended prophylaxis for venous thromboembolism compared with standard-duration prophylaxis intervention in acute medically ill patients: a systematic literature review and network meta-analysis.
Laskier V; Guy H; Fisher M; Neuman WR; Bucior I; Cohen AT; Ren S
J Med Econ; 2019 Oct; 22(10):1063-1072. PubMed ID: 31314619
[No Abstract] [Full Text] [Related]
17. New Paradigms of Extended Thromboprophylaxis in Medically Ill Patients.
MacDougall K; Spyropoulos AC
J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32252423
[TBL] [Abstract][Full Text] [Related]
18. Reducing the burden of venous thromboembolism in the acute medically ill population with extended-duration thromboprophylaxis.
Ageno W; Hunt BJ
Eur Heart J Suppl; 2018 May; 20(Suppl E):E6-E11. PubMed ID: 29977163
[TBL] [Abstract][Full Text] [Related]
19. A clinical focus on the use of extended-duration thromboprophylaxis in medically ill patients.
Snoga JL; Benitez RM; Kim S; Creager O; Lusk KA
Am J Health Syst Pharm; 2021 Jun; 78(12):1057-1065. PubMed ID: 33580664
[TBL] [Abstract][Full Text] [Related]
20. The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial.
Gibson CM; Halaby R; Korjian S; Daaboul Y; Arbetter DF; Yee MK; Goldhaber SZ; Hull R; Hernandez AF; Lu SP; Bandman O; Leeds JM; Gold A; Harrington RA; Cohen AT;
Am Heart J; 2017 Mar; 185():93-100. PubMed ID: 28267480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]